ABSTRACT
Objective:
To investigate the effects of intravenous thrombolysis combined with Xingnaojing
injection on
hemodynamic indexes and neurological function in
patients with
cerebral infarction.
Methods:
A total of 142
patients with
cerebral infarction who were treated in Xing An Meng
Hospital from April 2020 to May 2021 were included in this study. They were randomly divided into a
control group ( n = 71, intravenous thrombolysis) and a Xingnaojing
injection group ( n = 71, intravenous thrombolysis + Xingnaojing
injection). Intracranial arterial
hemodynamic indexes,
National Institutes of Health Stroke Scale score, Fugl-Meyer Assessment Scale score,
serum inflammatory factors,
oxidative stress indexes,
brain injury markers, and the
incidence of adverse reactions were compared between the two groups.
Results:
After treatment,
serum levels of
interleukin-1β,
interleukin-6, and
tumor necrosis factor-α were significantly lower in the Xingnaojing
injection group than the
control group [
interleukin-1β (4.05 ± 0.83) ng/L vs. (6.85 ± 1.02) ng/L,
interleukin-6 (43.61 ± 5.14) ng/L vs. (60.31 ± 7.04) ng/L,
tumor necrosis factor-α (35.93 ± 4.25) ng/L vs. (20.93 ± 3.11) ng/L, t = 17.94, 16.14, 15.37, all P < 0.001].
After treatment, the mean
blood flow velocities of the
anterior cerebral artery,
middle cerebral artery, and
posterior cerebral artery in the Xingnaojing
injection group were significantly higher than those in the
control group [
anterior cerebral artery (49.36 ± 5.28) cm/s vs. (41.15 ± 5.12) cm/s,
middle cerebral artery (61.27 ± 7.02) cm/s vs. (50.19 ± 6.08) cm/s,
posterior cerebral artery (44.92 ± 5.63) cm/s vs. (37.26 ± 4.93) cm/s, t = 9.40, 10.05, 8.62, all P < 0.001].
After treatment, the
National Institutes of Health Stroke Scale score and Fugl-Meyer Assessment Scale score in the Xingnaojing
injection group were superior to those in the
control group [
National Institutes of Health Stroke Scale score (10.36 ± 1.52) points vs. (14.62 ± 2.05) points, Fugl-Meyer Assessment Scale score (76.19 ± 8.08) points vs. (65.28 ± 7.14) points, t = 14.06, 8.52, both P < 0.05].
After treatment, the
serum level of
malondialdehyde in the Xingnaojing
injection group was significantly higher than that in the
control group [(6.35 ± 1.02) μmol/L vs. (10.05 ± 1.63) μmol/L), t = 16.21, P < 0.001]. The
serum level of
superoxide dismutase in the Xingnaojing
injection group was significantly lower than that in the
control group [(114.31 ± 13.69) U/L vs. (92.25 ± 10.16) U/L), t = 10.90, P < 0.001].
Serum levels of
neuron-specific enolase and S100β in the Xingnaojing
injection group were significantly lower than those in the
control group [
neuron-specific enolase (24.01 ± 3.24) IU/L vs. (30.31 ± 4.02) IU/L, S100β (0.73 ± 0.17) ng/L vs. (1.13 ± 0.22) ng/L, t = 10.28, 12.12, both P < 0.001). There was a significant difference in the
incidence of adverse reactions between the two groups ( P > 0.05).
Conclusion:
Intravenous thrombolysis combined with Xingnaojing
injection for the
treatment of
cerebral infarction can improve intracranial
hemodynamics, reduce the inflammatory response and
oxidative stress, and alleviate
brain tissue injury. The combined
therapy is beneficial to protect the neurological function of
patients with
cerebral infarction and is highly safe.